Rua Bioscience Limited — Interim / Quarterly Report 2024

Feb 28, 2024

Rua Bioscience Limited Results announcement

Results for announcement to the market	Results for announcement to the market	Results for announcement to the market	Results for announcement to the market
Name of issuer	Rua Bioscience Limited
Reporting Period	6 months to 31 December 2023
Previous Reporting Period	6 months to 31 December 2022
Currency	NZD
Amount (000s)		Percentage change
Revenue from continuing operations	$141	(44%)
Total Revenue	$141	(44%)
Net profit/(loss) from continuing operations	-$10,851	(1,610%)
Total net profit/(loss)	-$10,851	(1,610%)
Interim/Final Dividend
Amount per Quoted Equity Security	$0.00
Imputed amount per Quoted Equity Security	$0.00
Record Date	$0.00
Dividend Payment Date	$0.00
	Current period		Prior comparable period
Net tangible assets per Quoted Equity Security	$0.05		$0.07
A brief explanation of any of the figures above necessary to enable the figures to be understood	Refer unaudited interim financial statements
Authority for this announcement
Name of person authorised to make this announcement	Paul Naske
Contact person for this announcement	Paul Naske
Contact phone number	+64 (21) 445 154
Contact email address	Paul.naske@ruabio.com
Date of release through MAP	29 February 2024

Unaudited financial statements accompany this announcement.